Also known as: Moderna, Moderna Inc, Moderna Inc.
Moderna is a biotechnology company focused on mRNA medicines. The company says it is delivering the greatest possible impact through mRNA medicines and has built one of the industry's leading mRNA technology platforms since its founding in 2010.
WHO set the 2026-2027 northern hemisphere flu vaccine strains. Its FVIVA assessment says improved universal vaccines could prevent 18 billion cases and save 6.2 million lives by 2050.
Health care stocks rallied late in the week as Moderna beat Q4 expectations and reiterated its revenue outlook, lifting the sector. Novartis and AstraZeneca posted encouraging Phase 3 results, while Opus Genetics announced a $25 million private placement.
Moderna and Merck's personalized mRNA cancer vaccine, intismeran autogene, showed promising Phase 3 results in preventing melanoma recurrence. Combined with Keytruda, it cut recurrence risk by half and reduced spread by 59% in earlier data. The treatment could reach patients within two years pending regulatory approval.
Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
Merck and Moderna announced that their personalized mRNA cancer vaccine intismeran, combined with Keytruda, slowed melanoma recurrence in a late-stage trial. It is the first randomized Phase 3 trial to prove the benefit of neoantigen vaccines.
The FDA approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults 50 and older. Full approval covers ages 50-64; accelerated approval covers 65+. Moderna expects availability later this year, pending CDC recommendation.
A WashU Medicine study found Moderna's investigational mRNA flu vaccine could reduce hospitalizations and deaths, offering longer protection than current shots. If FDA-approved, it would be the first mRNA flu vaccine, with a decision possible by early August.
FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine for adults 50+. It was 27% more effective than standard flu shots in a large trial. The approval came after earlier FDA pushback.
Moderna posted a narrower-than-expected Q2 loss, with mFLUSIVA awaiting an FDA decision and a Phase 3 norovirus trial missing early success criteria. It reaffirmed 2026 revenue growth and cash guidance.
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05668741 |
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
